The 36-month beta value for KZR is at 0.28. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for KZR is 61.94M, and currently, shorts hold a 5.15% of that float. The average trading volume for KZR on July 04, 2024 was 755.18K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
KZR) stock’s latest price update
The stock of Kezar Life Sciences Inc (NASDAQ: KZR) has increased by 0.02 when compared to last closing price of 0.57.Despite this, the company has seen a loss of -9.67% in its stock price over the last five trading days. businesswire.com reported 2024-06-07 that SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar’.
KZR’s Market Performance
KZR’s stock has fallen by -9.67% in the past week, with a monthly drop of -19.56% and a quarterly drop of -33.52%. The volatility ratio for the week is 6.55% while the volatility levels for the last 30 days are 6.01% for Kezar Life Sciences Inc The simple moving average for the last 20 days is -13.77% for KZR’s stock, with a simple moving average of -34.03% for the last 200 days.
Analysts’ Opinion of KZR
Many brokerage firms have already submitted their reports for KZR stocks, with Wells Fargo repeating the rating for KZR by listing it as a “Equal Weight.” The predicted price for KZR in the upcoming period, according to Wells Fargo is $4 based on the research report published on August 11, 2023 of the previous year 2023.
Wells Fargo gave a rating of “Overweight” to KZR, setting the target price at $19 in the report published on December 08th of the previous year.
KZR Trading at -22.18% from the 50-Day Moving Average
After a stumble in the market that brought KZR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.12% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 6.55%, as shares sank -17.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.55% lower at present.
During the last 5 trading sessions, KZR fell by -8.24%, which changed the moving average for the period of 200-days by -55.11% in comparison to the 20-day moving average, which settled at $0.6550. In addition, Kezar Life Sciences Inc saw -39.82% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for KZR
Current profitability levels for the company are sitting at:
- -66.43 for the present operating margin
- 0.32 for the gross margin
The net margin for Kezar Life Sciences Inc stands at -64.46. The total capital return value is set at -0.57. Equity return is now at value -48.07, with -41.93 for asset returns.
Based on Kezar Life Sciences Inc (KZR), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -6.3. The debt to equity ratio resting at 0.08. The interest coverage ratio of the stock is -132.52.
Currently, EBITDA for the company is -104.17 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 17.44. The receivables turnover for the company is 0.51for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.49.
Conclusion
In conclusion, Kezar Life Sciences Inc (KZR) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
